FindTrial
Sign In

CTX112

BIOLOGICAL4 trials

Sponsors

CRISPR Therapeutics AG, CRISPR Therapeutics

Conditions

Autoimmune EncephalitisB-cell LymphomaB-cell MalignancyChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Diffuse Cutaneous Systemic SclerosisFollicular LymphomaITP - Immune ThrombocytopeniaImmune Thrombocytopenic Purpura

Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RecruitingNCT05643742
CRISPR Therapeutics AGB-cell Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) +5
Start: 2023-03-10End: 2030-02-28Target: 120Updated: 2025-11-14
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RecruitingNCT06925542
CRISPR TherapeuticsDiffuse Cutaneous Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Lupus Erythematosus, Systemic +4
Start: 2025-03-10End: 2031-12-31Target: 80Updated: 2026-08-28
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
RecruitingNCT07549698
CRISPR Therapeutics AGImmune Thrombocytopenic Purpura, ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia +1
Start: 2026-06-01End: 2033-12-01Target: 60Updated: 2026-07-22
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
Not yet recruitingNCT07804004
CRISPR TherapeuticsAutoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neuromyelitis Optica +2
Start: 2026-09-15End: 2029-12-30Target: 220Updated: 2026-09-09

Related Papers

CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies
Blood2024-11-057 citations
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
Regular and Young Investigator Award Abstracts2023-10-311 citations